Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$249.65 ▲ +5.60
(+2.30%)
MKT CAP: $36.90B • VOL: 1.16M
52W L $149 52W H $259
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$210
MEDIAN
$280
MEAN
$285
HIGH
$340
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BIIB TAPE
BIIB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $302.08 | $287.10 | 2025-02-14 | $227.18 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $314.56 | $294.59 | 2025-02-06 | $234.67 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $284.60 | $274.62 | 2025-01-29 | $239.66 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $254.64 | — | 2025-01-17 | $244.66 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $219.69 | $237.17 | 2025-01-09 | $222.19 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $297.08 | $259.64 | 2024-12-18 | $217.20 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $242.16 | $252.15 | 2024-12-04 | $232.17 | -4.3% | 48% | C |